Weak Statutory Earnings May Not Tell The Whole Story For Huarong Chemical (SZSE:301256)
Weak Statutory Earnings May Not Tell The Whole Story For Huarong Chemical (SZSE:301256)
The subdued market reaction suggests that Huarong Chemical Co., Ltd.'s (SZSE:301256) recent earnings didn't contain any surprises. However, we believe that investors should be aware of some underlying factors which may be of concern.
淡定的市場反應表明,華容化工股份有限公司(SZSE:301256)最近的收益沒有任何驚喜。然而,我們認爲投資者應該注意一些潛在的問題,這可能是令人擔憂的。
Examining Cashflow Against Huarong Chemical's Earnings
審視華容化工的現金流與收益
One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.
衡量公司將其利潤轉化爲自由現金流(FCF)的一項關鍵財務比率是應計比率。簡單地說,這個比率將FCF從淨利潤中減去,然後除以該公司在該期間的平均運營資產。您可以將從現金流中得出的應計比率視爲「非FCF利潤比率」。
Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".
因此,當公司的應計比率爲負時,實際上是一件好事,但如果其應計比率爲正,則是一件壞事。雖然應計比率爲零以上的事情無關緊要,但我們認爲當公司的應計比率相對較高時,值得注意。引用Lewellen和Resutek在2014年發表的一篇論文:「應計越高的公司未來利潤率越低」。
For the year to September 2024, Huarong Chemical had an accrual ratio of 0.35. We can therefore deduce that its free cash flow fell well short of covering its statutory profit, suggesting we might want to think twice before putting a lot of weight on the latter. Over the last year it actually had negative free cash flow of CN¥63m, in contrast to the aforementioned profit of CN¥98.4m. We also note that Huarong Chemical's free cash flow was actually negative last year as well, so we could understand if shareholders were bothered by its outflow of CN¥63m.
截至2024年9月的全年,華容化工的應計比率爲0.35。因此我們可以推斷,其自由現金流遠未覆蓋其法定利潤,這表明在給予後者很大權重之前,我們可能需要三思。過去一年,其實際自由現金流爲-6300萬元人民幣,與前述的9840萬元人民幣盈利形成對比。我們還注意到,華容化工去年實際上也是負的自由現金流,因此如果股東對其6.3億元人民幣流出感到不安,我們也能理解。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Huarong Chemical.
注意:我們始終建議投資者檢查資產負債表的實力。點擊這裏查看我們對華容化工資產負債表分析。
Our Take On Huarong Chemical's Profit Performance
我們對華融化工的盈利表現有自己的看法
As we discussed above, we think Huarong Chemical's earnings were not supported by free cash flow, which might concern some investors. As a result, we think it may well be the case that Huarong Chemical's underlying earnings power is lower than its statutory profit. Sadly, its EPS was down over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For instance, we've identified 3 warning signs for Huarong Chemical (2 make us uncomfortable) you should be familiar with.
正如我們前面討論的,我們認爲華融化工的盈利並未得到自由現金流的支持,這可能會讓一些投資者感到擔憂。結果,我們認爲華融化工的潛在盈利能力很可能低於其法定利潤。可悲的是,其每股收益在過去十二個月內下降了。本文的目標是評估我們能否依賴法定收益來反映公司的潛力,但還有很多要考慮的地方。因此,如果您希望更深入地了解這隻股票,就必須考慮它所面臨的任何風險。例如,我們已經確定了華融化工的3個警示信號(其中有2個讓我們感到不舒服),您應該熟悉。
This note has only looked at a single factor that sheds light on the nature of Huarong Chemical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
這篇文章僅僅看了影響華融化工盈利本質的一個因素。但是,如果您有能力專注於細枝末節,總會有更多發現。有些人認爲高淨資產回報率是優質企業的一個好跡象。雖然這可能需要您做一點研究,但您可能會發現這個免費的企業集合具有高淨資產回報率,或者這份具有重要內部持股的股票清單是有用的。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。